Invitation to 2cureX webcast and conference call on November 24, 2022
Kurs
+5,40%
Likviditet
0,04 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-02-27 | 15:00 | Bokslutskommuniké 2024 |
| 2024-12-18 | - | Extra Bolagsstämma 2024 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-24 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2024-05-23 | - | Årsstämma |
| 2024-02-22 | - | Bokslutskommuniké 2023 |
| 2023-11-23 | - | Kvartalsrapport 2023-Q3 |
| 2023-11-14 | - | Extra Bolagsstämma 2023 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-29 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-26 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2023-05-25 | - | Årsstämma |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2023-02-10 | - | Extra Bolagsstämma 2022 |
| 2022-11-24 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-25 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2022-05-24 | - | Årsstämma |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-25 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-28 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2021-05-27 | - | Årsstämma |
| 2021-05-27 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-26 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-02 | - | Extra Bolagsstämma 2020 |
| 2020-05-29 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2020-05-28 | - | Årsstämma |
| 2020-05-28 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-22 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-23 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-29 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2019-05-28 | - | Årsstämma |
| 2019-05-17 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-02 | - | Extra Bolagsstämma 2019 |
| 2019-03-01 | - | Bokslutskommuniké 2018 |
| 2018-11-23 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-29 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2018-05-28 | - | Årsstämma |
| 2018-05-18 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-15 | - | Bokslutskommuniké 2017 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, will publish its Q3 2022 report on Thursday November 24, 2022 at 8:30 CET.
2cureX will host a webcast on the same day at 10:00 CET and present its Q3 results. After the presentation there will be a Q&A session at which 2cureX’s Executive Management will answer any questions to the Q3 reporting and to the Strategy Deep-Dive held on November 15, 2022.
To join the webcast, simply click here: https://www.2curex.com/2curex-webinar-q3-2022/
For editors and the press
For more information, please contact:
Fernando Andreu
Chief Executive Officer
fa@2curex.com
About 2cureX
2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.
The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.
According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.
The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se